Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
Johnson & Johnson (NYSE: JNJ) announced that the World Health Organization (WHO) granted Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine. The vaccine shows a 67% reduction in symptomatic COVID-19 and 85% effectiveness against severe cases. This approval is pivotal for global vaccine distribution, particularly through the COVAX Facility, aiming to provide equitable access to lower-income countries. The vaccine's compatibility with standard storage and distribution makes it significant for pandemic response. Previous authorizations include Emergency Use Authorization in the U.S. and conditional approval in the EU.
Johnson & Johnson (NYSE: JNJ) announced that the CDC's Advisory Committee on Immunization Practices has recommended its single-shot COVID-19 vaccine for individuals 18 and older under Emergency Use Authorization (EUA) granted by the FDA. The vaccine, developed by Janssen, aims to enhance the U.S. national immunization program. Johnson & Johnson plans to deliver 100 million doses in the first half of 2021 and will file for a Biologics License Application later this year. The company is committed to making the vaccine available on a not-for-profit basis during the pandemic.
On February 27, 2021, Johnson & Johnson (NYSE: JNJ) announced that the FDA issued Emergency Use Authorization for its single-dose COVID-19 vaccine. The decision is based on Phase 3 ENSEMBLE study data showing 85% effectiveness in preventing severe disease. The company aims to deliver 100 million doses in the U.S. by mid-2021. The vaccine, which has not yet received full FDA approval, utilizes the AdVac® vaccine platform and presents advantages in storage and distribution, aiding in global vaccination efforts.
On Feb. 26, 2021, Johnson & Johnson (NYSE: JNJ) announced that the FDA's VRBPAC recommended Emergency Use Authorization for its single-shot COVID-19 vaccine for adults. The recommendation was based on the Phase 3 ENSEMBLE trial demonstrating safety and efficacy. If authorized, 20 million doses will be available by March, with a goal of 100 million by mid-2021. The vaccine can be stored at standard temperatures, enhancing distribution. The company is also pursuing approvals in Europe and other global markets to combat COVID-19.
On February 19, 2021, Johnson & Johnson announced that Janssen-Cilag International submitted an Emergency Use Listing for its single-dose COVID-19 vaccine candidate to the WHO. This submission follows the completion of the rolling data submission process, which includes interim results from the Phase 3 ENSEMBLE trial. The vaccine aims for equitable access, especially for lower-income countries, with plans to deliver up to 500 million doses via the COVAX Facility through Gavi. The Company is dedicated to global access on a not-for-profit basis during the pandemic.
Johnson & Johnson (NYSE: JNJ) announced on February 4, 2021, that Janssen Biotech has submitted an application to the FDA for Emergency Use Authorization of its single-dose COVID-19 vaccine. This submission is based on positive results from the Phase 3 ENSEMBLE trial, which met all primary endpoints. Once authorized, the vaccine will be ready for immediate distribution. The vaccine can be stored at -4°F for two years and at refrigeration temperatures for up to three months. The company is also engaging with global health authorities for further approvals.
On January 29, 2021, Johnson & Johnson (NYSE: JNJ) announced promising topline results from its Phase 3 ENSEMBLE clinical trial of a single-dose COVID-19 vaccine. The vaccine demonstrated 66% efficacy in preventing moderate to severe COVID-19, with effectiveness varying across regions. Notably, it achieved an 85% efficacy in preventing severe disease and complete protection against hospitalization and death, 28 days post-vaccination. The company plans to apply for Emergency Use Authorization in February, aiming for rapid distribution upon approval.
Johnson & Johnson (NYSE: JNJ) reported its 2020 financial results, showing a 0.6% increase in annual sales to $82.58 billion. The fourth-quarter sales rose by 8.3% to $22.48 billion. However, net earnings fell 56.7% YoY to $1.74 billion, with EPS declining to $0.65. The pharmaceutical sector saw an 8.0% increase in operational sales, while the medical devices segment faced an 11.6% decline due to COVID-19. The company remains optimistic about its ongoing COVID-19 vaccine efforts and potential future innovations.
Johnson & Johnson (NYSE: JNJ) has announced a cash dividend of $1.01 per share for the first quarter of 2021. This dividend is set to be paid on March 9, 2021, with shareholders of record on February 23, 2021. The ex-dividend date is February 22, 2021. This announcement reflects the company's ongoing commitment to returning value to shareholders.
Johnson & Johnson (NYSE: JNJ) appointed Dr. Nadja West, a retired U.S. Army lieutenant general and former Surgeon General, to its Board of Directors on December 3, 2020. Dr. West brings extensive healthcare leadership experience, having served as the Army Surgeon General from 2015 to 2019. Her strategic vision and commitment to public health are expected to enhance the Board's capabilities. CEO Alex Gorsky expressed optimism about her contributions at a crucial time for the company's mission to improve global health.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
